Form 4 for NMRA Neumora Therapeutics, Inc.
Accepted 2024-08-27 00:00:00 ET · period of report 2024-08-27 · accession 0001610717-24-000457 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TI | 2024-08-27 | 2024-08-27 | NMRA | Pinto Joshua | CFO | S - Sale | $11.39 | -15.7K | 139.0K | -10% | -$178.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-27 | S | D | 15,693 | $11.39 | 138,965 | I See footnote | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $11.1572 to $11.58, inclusive. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. (F3) Shares held by Maple DE Holdings LLC. |